Cascadian Therapeutics, Inc.
CASC
CASC was delisted on the 8th of March, 2018.
76 hedge funds and large institutions have $155M invested in Cascadian Therapeutics, Inc. in 2017 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 27 increasing their positions, 13 reducing their positions, and 21 closing their positions.
108% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 13
89% more call options, than puts
Call options by funds: $123K | Put options by funds: $65K
10% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 21
3% less funds holding
Funds holding: 78 → 76 (-2)
8% less capital invested
Capital invested by funds: $168M → $155M (-$13.1M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.55M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
+$1.79M |
| 3 |
SH
Sandia Holdings
Greenwich,
Connecticut
|
+$1.52M |
| 4 |
Boston Partners
Boston,
Massachusetts
|
+$1.51M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$4.61M |
| 2 |
QF
QVT Financial
New York
|
-$3.31M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.56M |
| 4 |
Millennium Management
New York
|
-$1.42M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$1.33M |
CASC Hedge Fund Activity: Q2 2017 in Review
76 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q2 2017, worth a combined $155M — down 7.8% from $168M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of CASC and 19 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 27 added.
The largest buyer was BlackRock, adding an estimated $5.55M. The largest seller was Franklin Resources, exiting entirely with an estimated $4.61M sold.
- 76 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q2 2017, down from 78 in Q1 2017.
- Funds reported $155M of Cascadian Therapeutics, Inc. stock for Q2 2017, down 7.8% quarter-over-quarter.
- 19 funds opened new Cascadian Therapeutics, Inc. positions in Q2 2017 and 21 closed out, a net change of -2 holders.
- The largest Cascadian Therapeutics, Inc. buyer in Q2 2017 was BlackRock, an estimated $5.55M added.
- The largest Cascadian Therapeutics, Inc. seller in Q2 2017 was Franklin Resources, an estimated $4.61M sold.
Based on aggregated 13F filings for Q2 2017.